for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-OBSEVA: Phase 2 Results Of Obe022 Expected In H2 2020

Jan 15 (Reuters) - OBSEVA SA:

* PHASE 3 LINZAGOLIX TRIALS EXPECTED TO GENERATE ADDITIONAL DATA IN UTERINE FIBROIDS IN Q2:20 WITH FIRST LINZAGOLIX REGULATORY FILING PLANNED FOR LATE 2020

* ENROLLMENT OF LINZAGOLIX US AND EU PHASE 3 TRIALS IN ENDOMETRIOSIS ON TRACK

* PHASE 2 RESULTS OF OBE022 EXPECTED IN 2H:20 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up